Free Trial
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel Free CAPR Stock Alerts

Capricor Therapeutics (CAPR) Financials

Capricor Therapeutics logo
$33.42 -0.96 (-2.79%)
As of 10:07 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for Capricor Therapeutics

Annual Income Statements for Capricor Therapeutics

This table shows Capricor Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -13 -19 2.43 -15 -7.64 -14 -20 -29 -22 -40 -105
Consolidated Net Income / (Loss)		 -13 -19 2.43 -15 -7.64 -14 -20 -29 -22 -40 -105
Net Income / (Loss) Continuing Operations		 -13 -19 2.43 -15 -7.64 -14 -20 -29 -22 -40 -105
Total Pre-Tax Income 		-13 -19 2.43 -15 -7.64 -14 -20 -29 -22 -40 -105
Total Operating Income		 -13 -17 -13 -15 -7.73 -14 -21 -30 -24 -43 -108
Total Gross Profit		 5.52 4.00 2.67 1.67 1.01 0.31 0.24 2.55 25 22 0.00
Total Revenue		 5.52 4.00 2.67 1.67 1.01 0.31 0.24 2.55 25 22 0.00
Operating Revenue		 5.52 4.00 2.67 1.67 1.01 0.31 0.24 2.55 25 22 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 18 21 16 17 8.74 14 21 32 49 65 108
Selling, General & Admin Expense		 4.37 4.93 4.76 4.93 3.60 5.54 7.61 10 13 15 24
Research & Development Expense		 14 16 11 12 5.14 8.46 14 22 36 50 84
Other Special Charges / (Income)		 - - - 0.00 - - 0.01 0.03 0.01 0.11 0.16
Total Other Income / (Expense), net		 -0.25 -1.83 15 0.14 0.09 0.03 0.92 0.71 1.79 2.21 3.26
Interest Expense		 0.25 0.34 0.40 - - 0.00 0.00 - - 0.00 3.05
Interest & Investment Income		 0.00 0.01 0.04 0.14 0.09 0.03 0.06 0.52 1.73 2.20 6.26
Other Income / (Expense), net		 0.00 -1.50 16 - -0.00 0.00 0.87 0.19 0.07 0.01 0.05
Income Tax Expense		 - - - - - - - - - 0.00 0.00
Basic Earnings per Share		 ($0.81) ($1.01) $0.10 ($5.17) ($2.06) - ($0.87) ($1.18) ($0.83) ($1.15) ($2.26)
Weighted Average Basic Shares Outstanding		 15.90M 18.55M 23.19M 2.94M 3.71M 15.57M 23.09M 24.55M 26.78M 35.22M 46.48M
Diluted Earnings per Share		 ($0.81) ($1.01) $0.09 ($5.17) ($2.06) - ($0.87) ($1.18) ($0.83) ($1.15) ($2.26)
Weighted Average Diluted Shares Outstanding		 15.90M 18.55M 26.79M 2.94M 3.71M 15.57M 23.09M 24.55M 26.78M 35.22M 46.48M
Weighted Average Basic & Diluted Shares Outstanding		 15.90M 18.55M 23.19M 2.94M 3.71M 15.57M 24.30M 25.26M 31.40M 45.68M 57.51M

Quarterly Income Statements for Capricor Therapeutics

This table shows Capricor Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -7.37 -6.46 -0.70 -9.79 -11 -13 -7.06 -24 -26 -25 -30
Consolidated Net Income / (Loss)		 -7.37 -6.39 -0.76 -9.79 -11 -13 -7.12 -24 -26 -25 -30
Net Income / (Loss) Continuing Operations		 -7.37 -6.39 -0.77 -9.79 -11 -13 -7.00 -24 -26 -25 -30
Total Pre-Tax Income 		-7.37 -6.39 -0.77 -9.79 -11 -13 -7.00 -24 -26 -25 -30
Total Operating Income		 -7.75 -6.86 -1.28 -10 -12 -13 -7.70 -25 -28 -26 -29
Total Operating Expenses		 12 13 13 15 16 15 19 25 28 26 29
Selling, General & Admin Expense		 2.85 3.02 3.43 4.07 3.06 3.46 4.27 6.07 5.67 5.92 6.02
Research & Development Expense		 8.82 10 9.94 11 13 12 15 19 22 20 23
Total Other Income / (Expense), net		 0.38 0.47 0.52 0.47 0.59 0.45 0.58 0.74 1.81 1.71 -1.01
Interest & Investment Income		 0.38 0.48 0.45 0.47 0.59 0.45 0.69 0.73 1.79 1.71 2.02
Other Income / (Expense), net		 - - - 0.00 0.00 0.00 - 0.01 0.01 0.01 0.01
Basic Earnings per Share		 ($0.29) ($0.25) $0.02 ($0.31) ($0.35) ($0.38) ($0.11) ($0.53) ($0.57) ($0.54) ($0.62)
Weighted Average Basic Shares Outstanding		 25.34M 25.82M 26.78M 31.35M 31.84M 33.09M 35.22M 45.64M 45.71M 45.72M 46.48M
Diluted Earnings per Share		 ($0.29) ($0.25) $0.02 ($0.31) ($0.35) ($0.38) ($0.11) ($0.53) ($0.57) ($0.54) ($0.62)
Weighted Average Diluted Shares Outstanding		 25.34M 25.82M 26.78M 31.35M 31.84M 33.09M 35.22M 45.64M 45.71M 45.72M 46.48M
Weighted Average Basic & Diluted Shares Outstanding		 25.78M 30.79M 31.40M 31.81M 32.54M 45.47M 45.68M 45.71M 45.72M 45.72M 57.51M

Annual Cash Flow Statements for Capricor Therapeutics

This table details how cash moves in and out of Capricor Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -2.47 -1.02 2.33 -2.34 -0.65 29 2.22 -25 5.09 -3.41 277
Net Cash From Operating Activities		 -11 -14 -14 -14 -6.82 -10 -17 4.92 -26 -40 -70
Net Cash From Continuing Operating Activities		 -11 -14 -14 -14 -6.82 -10 -17 4.92 -26 -40 -70
Net Income / (Loss) Continuing Operations		 -13 -19 2.43 -15 -7.64 -14 -20 -29 -22 -40 -105
Consolidated Net Income / (Loss)		 -13 -19 2.43 -15 -7.64 -14 -20 -29 -22 -40 -105
Depreciation Expense		 0.11 0.13 0.14 0.16 0.17 0.14 0.25 0.53 1.07 1.43 1.89
Non-Cash Adjustments To Reconcile Net Income		 1.67 3.46 -15 1.57 0.97 1.60 2.31 4.50 -2.45 9.83 31
Changes in Operating Assets and Liabilities, net		 0.26 0.77 -2.27 -0.40 -0.33 1.87 0.66 29 -1.93 -11 1.89
Net Cash From Investing Activities		 -8.14 -5.19 4.98 4.67 -3.00 5.44 -1.20 -35 5.11 -116 97
Net Cash From Continuing Investing Activities		 -8.14 -5.19 4.98 4.67 -3.00 5.44 -1.20 -35 5.11 -116 97
Purchase of Property, Plant & Equipment		 -0.15 -0.19 -0.03 -0.32 0.00 -0.55 -1.20 -2.00 -1.31 -1.17 -2.90
Purchase of Investments		 -18 -18 -19 -18 -6.00 -6.13 0.00 -114 -97 -208 -151
Sale and/or Maturity of Investments		 10 13 24 23 3.00 12 0.00 83 105 94 261
Other Investing Activities, net		 - - - - - - 0.00 -1.36 -0.74 -0.37 -8.82
Net Cash From Financing Activities		 16 19 12 6.85 9.18 33 20 4.87 26 153 249
Net Cash From Continuing Financing Activities		 16 19 12 6.85 9.18 33 20 4.87 26 153 249
Issuance of Common Equity		 16 14 11 6.71 9.17 27 20 4.80 26 152 237
Other Financing Activities, net		 - - 0.01 0.14 0.00 5.72 0.05 0.07 0.06 0.45 12
Cash Interest Paid		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Income Taxes Paid		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Quarterly Cash Flow Statements for Capricor Therapeutics

This table details how cash moves in and out of Capricor Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
Net Change in Cash & Equivalents		 -0.77 -0.85 5.71 -8.48 4.47 58 -57 18 -5.55 -3.73 268
Net Cash From Operating Activities		 -9.42 -8.79 -12 -1.27 -12 -12 -15 -6.43 -20 -20 -24
Net Cash From Continuing Operating Activities		 -9.42 -8.79 -12 -1.27 -12 -12 -15 -6.43 -20 -20 -24
Net Income / (Loss) Continuing Operations		 -7.37 -6.39 -0.76 -9.79 -11 -13 -7.12 -24 -26 -25 -30
Consolidated Net Income / (Loss)		 -7.37 -6.39 -0.76 -9.79 -11 -13 -7.12 -24 -26 -25 -30
Depreciation Expense		 0.25 0.28 0.31 0.33 0.36 0.36 0.38 0.41 0.49 0.49 0.50
Non-Cash Adjustments To Reconcile Net Income		 1.61 1.72 -7.97 13 2.14 2.00 -7.57 16 3.63 4.38 7.26
Changes in Operating Assets and Liabilities, net		 -3.92 -4.40 -3.17 -5.06 -3.79 -1.45 -0.49 1.37 1.67 0.01 -1.16
Net Cash From Investing Activities		 6.46 7.72 -5.86 -9.50 15 2.00 -123 24 15 16 43
Net Cash From Continuing Investing Activities		 6.46 7.72 -5.86 -9.50 15 2.00 -123 24 15 16 43
Purchase of Property, Plant & Equipment		 -0.14 -0.27 -0.56 -0.61 -0.06 -0.01 -0.49 -0.90 -0.29 -0.06 -1.66
Purchase of Investments		 -18 -20 -25 -33 -16 -20 -139 -18 -60 -58 -15
Sale and/or Maturity of Investments		 25 28 20 24 31 22 17 43 76 78 63
Other Investing Activities, net		 -0.10 -0.36 -0.17 -0.06 -0.02 -0.05 -0.25 -0.24 -1.16 -3.95 -3.46
Net Cash From Financing Activities		 2.19 0.22 23 2.29 2.07 67 81 0.05 0.02 0.01 249
Net Cash From Continuing Financing Activities		 2.19 0.22 23 2.29 2.07 67 81 0.05 0.02 0.01 249
Issuance of Common Equity		 2.13 0.22 23 2.29 1.99 67 81 0.00 - - 237
Other Financing Activities, net		 0.06 - 0.00 0.00 0.08 0.12 0.25 0.05 0.02 0.01 12

Annual Balance Sheets for Capricor Therapeutics

This table presents Capricor Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 16 19 16 9.25 11 35 41 50 59 170 356
Total Current Assets		 14 18 16 8.47 11 34 36 43 51 163 323
Cash & Equivalents		 5.57 3.20 6.14 4.26 3.90 33 35 9.60 15 11 288
Short-Term Investments		 8.00 13 7.98 3.00 5.99 - 0.00 32 25 140 30
Prepaid Expenses		 0.21 0.34 0.50 0.72 0.57 1.01 1.16 0.92 1.00 1.50 4.75
Other Current Assets		 0.21 0.22 0.34 0.20 0.09 0.00 0.39 0.55 10 10 0.06
Plant, Property, & Equipment, net		 0.32 0.44 0.37 0.57 0.44 0.85 1.80 4.59 5.56 5.56 18
Total Noncurrent Assets		 1.76 0.20 0.19 0.20 0.13 0.09 3.10 2.35 2.32 1.53 15
Other Noncurrent Operating Assets		 0.07 0.06 0.10 0.15 0.12 0.09 3.10 2.35 2.32 1.53 15
Total Liabilities & Shareholders' Equity		 16 19 16 9.25 11 35 41 50 59 170 356
Total Liabilities		 17 23 5.05 4.63 4.27 6.42 9.96 38 36 25 50
Total Current Liabilities		 6.53 4.90 1.67 1.26 0.90 2.97 4.13 24 31 21 36
Accounts Payable		 2.88 3.53 1.67 1.26 0.90 2.72 3.72 4.83 6.25 3.28 1.65
Accrued Expenses		 - - - - - - - - - 4.91 16
Current Deferred Revenue		 3.65 1.37 - - - - 0.00 18 24 12 12
Other Current Liabilities		 - - - - - - 0.42 0.77 0.75 0.83 6.62
Total Noncurrent Liabilities		 11 18 3.38 3.38 3.38 3.45 5.83 15 4.86 3.99 14
Other Noncurrent Operating Liabilities		 0.51 3.95 3.38 3.38 3.38 3.38 2.45 1.88 4.86 3.99 14
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -1.03 -4.00 11 4.62 6.84 28 31 12 23 145 306
Total Preferred & Common Equity		 -1.03 -4.00 11 4.62 6.84 28 31 12 23 145 306
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -1.03 -4.00 11 4.62 6.84 28 31 12 23 145 306
Common Stock		 34 50 63 71 81 116 139 149 182 344 610
Retained Earnings		 -35 -54 -52 -67 -74 -88 -108 -137 -159 -200 -305
Accumulated Other Comprehensive Income / (Loss)		 0.01 0.00 0.01 0.01 -0.00 - 0.00 0.11 0.24 1.03 0.28

Quarterly Balance Sheets for Capricor Therapeutics

This table presents Capricor Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025
Total Assets		 54 54 46 37 49 38 93 154 134 126
Total Current Assets		 48 47 39 30 41 31 86 146 124 101
Cash & Equivalents		 8.41 11 9.84 8.98 6.21 11 68 29 23 20
Short-Term Investments		 38 35 28 20 34 19 17 116 100 79
Prepaid Expenses		 0.34 0.88 0.58 0.46 1.13 0.84 0.39 1.41 1.27 2.33
Other Current Assets		 0.55 0.55 0.55 0.55 0.37 0.37 0.41 0.06 0.06 0.06
Plant, Property, & Equipment, net		 3.59 4.81 4.79 5.14 5.89 5.62 5.32 6.13 8.00 11
Total Noncurrent Assets		 2.83 2.19 2.03 2.49 1.85 1.99 1.81 1.38 1.45 14
Other Noncurrent Operating Assets		 2.83 2.19 2.03 2.49 1.85 1.99 1.81 1.38 1.45 14
Total Liabilities & Shareholders' Equity		 54 54 46 37 49 38 93 154 134 126
Total Liabilities		 39 48 43 39 31 27 25 26 29 43
Total Current Liabilities		 23 37 35 33 26 22 20 22 28 28
Accounts Payable		 3.94 5.41 5.13 6.77 6.25 6.17 6.53 5.25 4.81 2.72
Accrued Expenses		 - - - - - - - 4.24 7.36 9.93
Current Deferred Revenue		 19 31 29 25 19 15 13 12 12 12
Other Current Liabilities		 0.70 0.69 0.71 0.75 0.77 0.79 0.81 0.84 4.23 3.50
Total Noncurrent Liabilities		 15 11 8.13 6.01 4.63 4.42 4.21 3.78 0.19 14
Other Noncurrent Operating Liabilities		 2.08 1.70 1.52 1.68 1.25 1.04 0.83 3.78 0.19 14
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 15 6.21 2.73 -1.79 18 12 68 128 105 84
Total Preferred & Common Equity		 15 6.21 2.73 -1.79 18 12 68 128 105 84
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 15 6.21 2.73 -1.79 18 12 68 128 105 84
Common Stock		 145 151 155 157 187 192 261 350 354 358
Retained Earnings		 -129 -145 -152 -159 -169 -180 -193 -224 -250 -275
Accumulated Other Comprehensive Income / (Loss)		 0.12 0.09 0.18 0.11 0.31 0.15 0.10 1.81 1.39 0.84

Annual Metrics And Ratios for Capricor Therapeutics

This table displays calculated financial ratios and metrics derived from Capricor Therapeutics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 16,254,985.00 21,399,019.00 25,710,074.00 31,067,359.00 4,246,225.00 20,447,504.00 24,149,155.00 - - - 45,718,475.00
DEI Adjusted Shares Outstanding		 1,625,498.00 2,139,902.00 2,571,007.00 3,106,736.00 4,246,225.00 20,447,504.00 24,149,155.00 - - - 45,718,475.00
DEI Earnings Per Adjusted Shares Outstanding		 -7.91 -8.79 0.95 -4.89 -1.80 -0.67 -0.83 - - - -2.30
Growth Metrics		 - - - - - - - - - - -
Profitability Metrics		 - - - - - - - - - - -
Net Operating Profit after Tax (NOPAT)		 -8.83 -12 -13 -11 -5.41 -9.58 -15 -21 -17 -30 -76
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -74.57% -20.48% -24.76%
Earnings before Interest and Taxes (EBIT)		 -13 -18 2.79 -15 -7.74 -14 -20 -30 -24 -43 -108
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -13 -18 2.94 -15 -7.56 -14 -20 -29 -23 -41 -106
Valuation Ratios		 - - - - - - - - - - -
Leverage & Solvency		 - - - - - - - - - - -
Liquidity Ratios		 - - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -11 -9.69 -17 -11 -5.29 -8.48 -19 5.60 -26 -41 -69
Efficiency Ratios		 - - - - - - - - - - -
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -5.44 -7.64 -3.64 -2.93 -3.05 -4.15 -0.14 -27 -17 -6.05 -12
Increase / (Decrease) in Invested Capital		 2.66 -2.20 4.00 0.71 -0.12 -1.10 4.01 -26 9.64 11 -6.28
Book Value per Share		 ($0.06) ($0.19) $0.44 $0.15 $1.61 $1.38 $1.30 $0.47 $0.73 $3.20 $6.69
Tangible Book Value per Share		 ($0.17) ($0.19) $0.43 $0.15 $1.61 $1.38 $1.30 $0.47 $0.73 $3.20 $6.69
Total Capital		 8.12 9.90 11 4.62 6.84 29 35 15 23 145 306
Total Debt		 9.16 14 0.00 0.00 0.00 0.32 3.38 3.38 0.00 0.00 0.00
Total Long-Term Debt		 9.16 14 0.00 0.00 0.00 0.07 3.38 3.38 0.00 0.00 0.00
Net Debt		 -4.41 -3.64 -15 -7.54 -9.89 -32 -32 -38 -39 -152 -318
Capital Expenditures (CapEx)		 0.15 0.19 0.03 0.32 0.00 0.55 1.20 2.00 1.31 1.17 2.90
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -6.11 -4.33 -0.82 -0.33 -0.24 -1.71 -2.58 -22 -20 -9.16 -31
Debt-free Net Working Capital (DFNWC)		 7.46 13 14 7.22 9.65 31 32 19 20 142 287
Net Working Capital (NWC)		 7.46 13 14 7.22 9.65 31 32 19 20 142 287
Net Nonoperating Expense (NNE)		 4.03 6.92 -15 4.46 2.23 4.07 5.37 8.23 5.43 11 29
Net Nonoperating Obligations (NNO)		 -4.41 -3.64 -15 -7.54 -9.89 -32 -32 -38 -39 -152 -318
Total Depreciation and Amortization (D&A)		 0.11 0.13 0.14 0.16 0.17 0.14 0.25 0.53 1.07 1.43 1.89
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($8.10) ($10.10) $1.00 ($5.20) ($2.06) ($0.88) $0.00 ($1.18) ($0.83) ($1.15) ($2.26)
Adjusted Weighted Average Basic Shares Outstanding		 1.80M 2.14M 2.32M 3.37M 8.91M 22.80M 23.09M 24.55M 26.78M 35.22M 46.48M
Adjusted Diluted Earnings per Share		 ($8.10) ($10.10) $0.90 ($5.20) ($2.06) ($0.88) $0.00 ($1.18) ($0.83) ($1.15) ($2.26)
Adjusted Weighted Average Diluted Shares Outstanding		 1.80M 2.14M 2.68M 2.94M 8.91M 22.80M 23.09M 24.55M 26.78M 35.22M 46.48M
Adjusted Basic & Diluted Earnings per Share		 ($8.10) ($10.10) $0.00 ($5.20) ($2.06) ($0.88) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 1.59M 1.86M 2.77M 2.94M 3.71M 15.57M 24.30M 25.26M 31.40M 45.68M 57.51M
Normalized Net Operating Profit after Tax (NOPAT)		 -8.83 -12 -9.00 -11 -5.41 -9.58 -15 -21 -17 -30 -76
Debt Service Ratios		 - - - - - - - - - - -
Payout Ratios		 - - - - - - - - - - -

Quarterly Metrics And Ratios for Capricor Therapeutics

This table displays calculated financial ratios and metrics derived from Capricor Therapeutics' official financial filings.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
DEI Shares Outstanding		 - - - - - - - 45,676,202.00 45,707,819.00 45,716,975.00 45,718,475.00
DEI Adjusted Shares Outstanding		 - - - - - - - 45,676,202.00 45,707,819.00 45,716,975.00 45,718,475.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - -0.53 -0.57 -0.54 -0.66
Growth Metrics		 - - - - - - - - - - -
Profitability Metrics		 - - - - - - - - - - -
Net Operating Profit after Tax (NOPAT)		 -5.42 -4.81 -0.90 -7.19 -8.11 -9.11 -5.39 -17 -19 -18 -20
Return On Investment Capital (ROIC_SIMPLE)		 - - -3.97% - - - -3.70% -13.70% -18.48% -21.94% -6.67%
Earnings before Interest and Taxes (EBIT)		 -7.75 -6.86 -1.28 -10 -12 -13 -7.70 -25 -28 -26 -29
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -7.49 -6.59 -0.97 -9.93 -11 -13 -7.32 -25 -27 -26 -29
Valuation Ratios		 - - - - - - - - - - -
Leverage & Solvency		 - - - - - - - - - - -
Liquidity Ratios		 - - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -2.78 -5.68 -11 -25 -25 -23 -16 -19 -16 -17 -14
Efficiency Ratios		 - - - - - - - - - - -
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -32 -27 -17 -18 -15 -13 -6.05 -17 -18 -15 -12
Increase / (Decrease) in Invested Capital		 -2.64 0.88 9.64 17 17 14 11 1.27 -3.24 -1.31 -6.28
Book Value per Share		 $0.11 ($0.07) $0.73 $0.59 $0.36 $2.10 $3.20 $2.79 $2.30 $1.83 $6.69
Tangible Book Value per Share		 $0.11 ($0.07) $0.73 $0.59 $0.36 $2.10 $3.20 $2.79 $2.30 $1.83 $6.69
Total Capital		 6.11 1.59 23 22 15 72 145 128 105 84 306
Total Debt		 3.38 3.38 0.00 3.38 3.38 3.38 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 3.38 3.38 0.00 3.38 3.38 3.38 0.00 0.00 0.00 0.00 0.00
Net Debt		 -34 -25 -39 -37 -26 -82 -152 -145 -123 -99 -318
Capital Expenditures (CapEx)		 0.14 0.27 0.56 0.61 0.06 0.01 0.49 0.90 0.29 0.06 1.66
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -34 -32 -20 -25 -21 -20 -9.16 -21 -27 -26 -31
Debt-free Net Working Capital (DFNWC)		 3.77 -3.40 20 15 8.31 65 142 124 96 73 287
Net Working Capital (NWC)		 3.77 -3.40 20 15 8.31 65 142 124 96 73 287
Net Nonoperating Expense (NNE)		 1.94 1.59 -0.13 2.61 2.89 3.45 1.73 6.90 6.51 6.17 9.76
Net Nonoperating Obligations (NNO)		 -35 -25 -39 -37 -26 -82 -152 -145 -123 -99 -318
Total Depreciation and Amortization (D&A)		 0.25 0.28 0.31 0.33 0.36 0.36 0.38 0.41 0.49 0.49 0.50
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.29) ($0.25) $0.02 ($0.31) ($0.35) ($0.38) ($0.11) ($0.53) ($0.57) ($0.54) ($0.62)
Adjusted Weighted Average Basic Shares Outstanding		 25.34M 25.82M 26.78M 31.35M 31.84M 33.09M 35.22M 45.64M 45.71M 45.72M 46.48M
Adjusted Diluted Earnings per Share		 ($0.29) ($0.25) $0.02 ($0.31) ($0.35) ($0.38) ($0.11) ($0.53) ($0.57) ($0.54) ($0.62)
Adjusted Weighted Average Diluted Shares Outstanding		 25.34M 25.82M 26.78M 31.35M 31.84M 33.09M 35.22M 45.64M 45.71M 45.72M 46.48M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 25.78M 30.79M 31.40M 31.81M 32.54M 45.47M 45.68M 45.71M 45.72M 45.72M 57.51M
Normalized Net Operating Profit after Tax (NOPAT)		 -5.42 -4.80 -0.90 -7.19 -8.11 -9.11 -5.39 -17 -19 -18 -20
Debt Service Ratios		 - - - - - - - - - - -
Payout Ratios		 - - - - - - - - - - -

Financials Breakdown Chart

Key Financial Trends

Capricor Therapeutics (CAPR) has shown a pattern of substantial financing activity to fund ongoing operations, with persistent net losses and limited revenue. Below are the key trends observed across the last four years, focusing on cash flow, income, and equity evolution.

  • Large equity financing in 2025 Q4: Issuance of common stock worth 237,033,938 USD drove net financing inflows of 248,815,412 USD and led to a substantial cash increase (Net Change in Cash: 268,336,929 USD).
  • Expansion of total equity via stock issuances: Total Common Equity rose from about 68.3 million USD at 2024 Q4 to roughly 104.98 million USD by 2025 Q2, reflecting ongoing capital raises to support operations.
  • Investors generating liquidity from investments: Significant selling/maturity of investments produced sizable cash inflows—78,175,291 USD in 2025 Q3 and 63,212,777 USD in 2025 Q4—helping offset some cash burn.
  • Quarterly financing activity remains a core liquidity source: Net Cash From Financing Activities was substantial in 2024 Q4 (≈81.1 million USD) and remained strong in 2025 Q4 (≈248.8 million USD), indicating heavy reliance on external financing to fund operations.
  • Revenue remains largely non-existent in 2025: Operating revenue was zero in multiple 2025 quarters, with sporadic, small revenue in earlier years, underscoring continued reliance on financing rather than operating performance for liquidity.
  • Negative cash flow from operating activities persists in 2025: Net cash from continuing operating activities remained negative across 2025 quarters (roughly -6.4M to -23.6M USD per quarter), signaling ongoing cash burn despite financing inflows.
  • Accumulated losses grow despite equity raises: Retained earnings declined further into 2024–2025 (e.g., about -224.2M USD at 2024 Q4 and around -274.7M USD by 2025 Q3), indicating cumulative losses beyond new equity issued.
  • Material quarterly net losses persist: Net income / loss from continuing operations was deeply negative in 2025 (e.g., -30.17M USD in 2025 Q4 and -24.57M USD in 2025 Q3), reflecting ongoing profitability challenges.
  • Ongoing cash burn with limited near-term profitability: The combination of negative operating cash flow, zero core revenue in many quarters, and sizable net losses reinforces a fragile near-term financial position without sustained revenue growth.
05/07/26 10:07 AM ETAI Generated. May Contain Errors.

Frequently Asked Questions About Capricor Therapeutics' Financials

When does Capricor Therapeutics' fiscal year end?

According to the most recent income statement we have on file, Capricor Therapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

How has Capricor Therapeutics' net income changed over the last 10 years?

Capricor Therapeutics' net income appears to be on an upward trend, with a most recent value of -$105.04 million in 2025, rising from -$12.86 million in 2015. The previous period was -$40.47 million in 2024. Check out Capricor Therapeutics' forecast to explore projected trends and price targets.

What is Capricor Therapeutics' operating income?
Capricor Therapeutics' total operating income in 2025 was -$108.14 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $108.30 million
How has Capricor Therapeutics' revenue changed over the last 10 years?

Over the last 10 years, Capricor Therapeutics' total revenue changed from $5.52 million in 2015 to $0.00 in 2025, a change of -100.0%.

How much debt does Capricor Therapeutics have?

Capricor Therapeutics' total liabilities were at $50.16 million at the end of 2025, a 100.5% increase from 2024, and a 193.3% increase since 2015.

How much cash does Capricor Therapeutics have?

In the past 10 years, Capricor Therapeutics' cash and equivalents has ranged from $3.20 million in 2016 to $287.85 million in 2025, and is currently $287.85 million as of their latest financial filing in 2025.

How has Capricor Therapeutics' book value per share changed over the last 10 years?

Over the last 10 years, Capricor Therapeutics' book value per share changed from -0.06 in 2015 to 6.69 in 2025, a change of -10,633.2%.


Related Companies

Financial statements for NASDAQ:CAPR last updated on 4/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Before you buy SpaceX shares, consider this alternative approach
SpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceedin...
Weiss Ratings | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel
Invest in SpaceX Before IPO
SpaceX is already one of the most valuable private companies on Earth, and some analysts believe its valuation...
NXT Wave Research | Sponsoredtc pixel
Satellite Images Spot Potential $10 Trillion Discovery
'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...
Altimetry | Sponsoredtc pixel